Lonza Pharma & Biotech has launched its pharmaceutical early-intermediates supply initiative. The initiative leverages chemical production facilities at the company’s Visp, Switzerland site to address increasing global early-intermediates supply security and quality concerns. Lonza now offers its customers an integrated supply chain from non-GMP early intermediates to cGMP advanced intermediates and active pharmaceutical ingredients (APIs). Lonza will supply ISO-certified early inte...